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Abstract
The nuclear receptor FXR acts as an intracellular bile salt sensor that regulates
synthesis and transport of bile salts within their enterohepatic circulation. In
addition, FXR is involved in control of a variety of crucial metabolic pathways. Four
FXR splice variants are known, i.e. FXRa1-4. Although these isoforms show
differences in spatial and temporal expression patterns as well as in transcriptional
activity, the physiological relevance hereof has remained elusive. We have
evaluated specific roles of hepatic FXRa2 and FXRa4 by stably expressing these
isoforms using liver-specific self-complementary adeno-associated viral vectors in
total body FXR knock-out mice. The hepatic gene expression profile of the FXR
knock-out mice was largely normalized by both isoforms. Yet, differential effects
were also apparent; FXRa2 was more effective in reducing elevated HDL levels
and transrepressed hepatic expression of Cyp8b1, the regulator of cholate
synthesis. The latter coincided with a switch in hydrophobicity of the bile salt pool.
Furthermore, FXRa2-transduction caused an increased neutral sterol excretion
compared to FXRa4 without affecting intestinal cholesterol absorption. Our data
show, for the first time, that hepatic FXRa2 and FXRa4 differentially modulate bile
salt and lipoprotein metabolism in mice.
Introduction
Bile salts are synthesized from cholesterol by well-characterized biosynthetic
pathways (see [1] for review). The neutral pathway starts with 7a-hydroxylation
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of cholesterol by cholesterol 7a-hydroxylase (Cyp7a1) and the acidic pathway is
initiated by sterol 27-hydroxylase (Cyp27a1). Newly synthesized primary bile salts
are cholate (CA) and chenodeoxycholate (CDCA) in humans, whereas in rodents
CDCA is rapidly converted into the more hydrophilic muricholates (MCA). Sterol
12a-hydroxylase (Cyp8b1) is required for the biosynthesis of CA and determines
the ratio CA to CDCA. The chemical diversity of bile salts is further expanded by
conjugation to either taurine or glycine and by the actions of intestinal bacteria
via deconjugation, oxidation of hydroxyl groups and dehydroxylation, creating a
bile salt pool with specific physiochemical properties. In addition to their well-
established functions in generation of bile formation by the liver and absorption
of dietary fats and fat-soluble vitamins from the intestine, bile salts are now
recognized to act as ‘integrators of metabolism’ [1, 2].
Bile salts contribute to control of a broad range of metabolic pathways,
including their own synthesis in liver and transport within the enterohepatic
circulation, via activation of the Farnesoid X Receptor (FXRa/NR1H4, referred to
as FXR) [3, 4]. FXR, a member of the nuclear hormone receptor superfamily, has
four splice variants in humans and rodents [5, 6]. These isoforms arise from a
single gene through alternative splicing of exon 5 and the use of distinct
promoters that initiate transcription from either exon 1 or exon 3. The different
promoters of the FXR gene initiate expression of either FXRa1 and FXRa2 or of
FXRa3 and FXRa4 transcripts. FXR isoforms show differences in spatial and
temporal expression as well as in transcriptional activity [6]. FXRa1 and FXRa3
transcripts contain four additional amino acids in the hinge domain, adjacent to
the DNA-binding domain, which make these two isoforms less transcriptionally
active compared to FXRa2 and FXRa4. In mice all four isoforms are abundantly
expressed in liver, while FXRa3 and a4 are abundantly expressed in ileum,
moderately in kidney and at low levels in stomach, duodenum, and jejunum.
Furthermore, FXRa1 and a2 are moderately expressed in ileum and adrenal gland
[6].
In the liver, bile salt-activated FXR suppresses, amongst others, Cyp7a1
expression, in a Short Heterodimer Partner(SHP/NR0B2)- and Liver Receptor
Homolog-1 (LRH-1/NR5A2)-dependent manner [7, 8]. Also Cyp8b1 and
Cyp27a1 are regulated by FXR, in a SHP- and Hepatocyte Nuclear Factor-4a
(HNF4A)-dependent manner [9, 10]. In the past decade, FXR has emerged as an
important regulator of lipid as well as glucose homeostasis and to have anti-
inflammatory properties [1]. Hence, FXR is considered a promising target for
treatment of a number of metabolic and liver diseases. Treatment with synthetic
FXR agonists showed improved insulin sensitivity in diabetic mouse models
[11, 12] and prevented formation of atherosclerotic plaques in atherogenic-prone
mice [13]. Furthermore, administration of the semi-synthetic obeticholic acid
(OCA) increased insulin sensitivity and reduced markers of liver inflammation
and fibrosis in patients with type 2 diabetes and nonalcoholic fatty liver disease
[14].
In light of the increasing evidence for the therapeutic potential of FXR agonists
in the regulation of lipid metabolism, we addressed the specific roles of FXRa2
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and FXRa4, the transcriptionally most active isoforms of FXR [5, 6], on bile salt
and lipid metabolism in vivo by means of a liver-specific FXRa2 or FXRa4
expressing mouse model. Our data revealed some distinct functions of FXRa2 and
FXRa4 in control of plasma cholesterol levels; only hepatic FXRa2 expression
could rescue the elevated plasma HDL levels of FXR KO mice. Moreover, FXRa2
and FXRa4 were found to differentially regulate Cyp8b1 expression in vivo, which
coincided with compositional changes in the respective bile salt pools. Our data
show, for the first time, that hepatic FXRa2 and FXRa4 differentially modulate
bile salt and lipoprotein metabolism in mice.
Materials and Methods
Construction and production of self-complementary AAV vectors
The coding sequences of murine FXRa1, FXRa3, HNF4a, SHP and RXRa were
amplified using specific primer pairs harboring a Kozak consensus ATG initiation
codon and a BamH1 restriction side at the 59 end and a Not1 restriction side at the
39 end (S1 Table) [15]. As a template source, cDNA was synthesized from hepatic
RNA from C57BL/6J wild-type mice. The products were cloned into pcDNA5/
FRT/TO (Invitrogen, Life Technologies, Bleiswijk, The Netherlands). The
presence of the correct gene was sequence-verified. Subsequently, the MYTG
insertion was deleted from FXRa1 and a3 using inverse PCR primers, to generate
FXRa2 and FXRa4. Self-complementary AAV (scAAV) serotype 8 vectors with the
liver specific LP1 promoter driving murine FXRa2 or murine FXRa4 expression
were generated by replacing the factor IX of scAAV2-LP1-hFIXco [16, 17] using
Pme1, EcoR1 and Hpa1. Additionally, AAV8- pseudotyped vectors were made
using the packaging plasmid pAAV8-2. Production, purification and titration of
all vectors were performed as described [18, 19].
Cell culture, transfections and reporter assays
CV1 cells (a kind gift from Ronald M. Evans, Salk Institute, San Diego, USA) were
maintained in DMEM (Gibco, Breda, The Netherlands) supplemented with 10%
FCS (Sigma Aldrich Chemie BV, Zwijndrecht, The Netherlands), 100 U/ml
penicillin and 100 mg/ml streptomycin (Gibco, Breda, The Netherlands). Cultures
were maintained at 37 C˚ and 5% CO2 in a humidified incubator. Cells were
transiently transfected using FuGENE 6 transfection reagent (Promega, Leiden,
The Netherlands) according to manufacturer’s protocol. Cell lysis and luciferase
assays were performed using a dual luciferase reporter assay system (Promega,
Leiden, The Netherlands) according to manufacturer’s protocol. Briefly, the
human PGL4-SHP (CHR1_M0312_R1, Switchgear Genomics, Menlo Park, CA,
USA) and Cyp8b1 [20] (a kind gift from John Y. Chiang, Northeastern Ohio
Medical University, Rootstown, USA) promoter reporters were cotransfected
together with the pcDNA5/FRT/TO murine FXR isoforms and the heterodimer
FXR Isoforms Differentially Modulate Bile Salt Metabolism
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RXR alpha/NR2B1 for 48 hrs. Cells were treated with 50 mM CDCA 24 prior to
cell lysis when stated.
Animal experiments
FXR knock-out mice [21] backcrossed on a C57BL/6J background and C57BL/6J
wild-type mice were housed individually in a temperature- and light-controlled
facility with 12 hours light-dark cycling and received food and water ad libitum.
Experiments were approved by the Ethical Committee for Animal Experiments of
the University of Groningen. Age-matched male FXR knock-out received 161011
AAV vector genomes or PBS injected into the retro-orbital sinus. PBS-injection,
rather than AAV-injected was used as control since GFP from our AAV-GFP
induced several responses, which was already know from previous studies [22, 23].
When indicated, mice received chow (RMH-B, Hope Farms, Woerden, The
Netherlands) supplemented with 0.5% (w/w) cholate (Calbiochem, La Jolla, CA,
USA) in the final week before termination.
Experimental procedures
Four weeks after the scAAV injections, cholesterol fluxes were measured as
described previously [24]. Briefly, at day 0 mice received an intravenous dose of
0.3 mg (0.73 mmol) cholesterol-D7 (Cambridge Isotope Laboratories, Inc,
Andover, MA, USA) dissolved in Intralipid (20%, Fresenius Kabi, Den Bosch, The
Netherlands) and an oral dose of 0.6 mg (1.535 mmol) cholesterol-D5 (Medical
Isotopes, Inc, Pelham, NH, USA) dissolved in MCT oil (Pharmacy UMCG,
Groningen, The Netherlands). Blood spots were collected from the tail daily for 10
days. At the end of the experiment, mice were anesthetized and after puncturing
the gallbladder and disposal of its contents, hepatic bile was collected for
20 minutes from the common bile duct via the gallbladder [25]. Tissues were
excised and feces was collected from individual mice for 72 hours prior to
termination.
Analytical procedures
Hepatic lipids were extracted according to Bligh & Dyer [26]. Plasma and liver
triglycerides, total cholesterol and free cholesterol contents were determined using
commercially available kits (Roche Diagnostics, Mannheim, Germany and DiaSys
Diagnostic Systems, Holzheim, Germany). Plasma levels of alanine aminotrans-
ferase (ALAT) and aspartate aminotransferase (ASAT) were determined using
commercially available kits (Spinreact, Santa Coloma, Spain). Biliary phospho-
lipid content was determined according to Bo¨ttcher et al. [27]. Cholesterol in bile
was measured according to Gamble et al. [28]. Pooled plasma samples were
subjected to fast protein liquid chromatography (FPLC) gel filtration using a
Superose 6 column (GE Healthcare, Little Chalfont, UK). Biliary and fecal bile salt
composition were quantified using capillary gas chromatography (Hewlett-
Packerd gas chromatograph; HP 6890) equipped with a FID and a CP Sil 19
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capillary column; length 25 m, internal diameter 250 mm and a film thickness of
0.2 mm (Chrompack BV, Middelburg, The Netherlands). Bile salts were
methylated with a mixture of methanol and acetyl chloride and trimethylsilylated
with piridyne, N, O-Bis(trimethylsilyl) trifluoroacetamide and trimethylchlor-
osilane. The murine bile salt species include cholate (CA), deoxycholate (DCA),
chenodeoxycholate (CDCA), a-muricholate (a-MCA), b-muricholate (b-MCA),
v-muricholate (v-MCA), hyodeoxycholate (HDCA), lithocholate (LCA) and
ursodeoxycholate (UDCA). We consider cholate and deoxycholate as CA-derived
bile salts and the others as CDCA-derived bile salts. Fecal cholesterol and its
derivatives (also known as neutral sterols) were trimethylsilylated with pyridine,
N, O-Bis (trimethylsilyl) trifluoroacetamide and trimethylchlorosilane and
measured on the GC equipped with the same column. Cholesterol enrichment was
determined by capillary gas chromatography on a Agilent gas chromatograph
(7890A; Amstelveen, The Netherlands) equipped with a 30 m60.25 mm column,
with a film thickness of 0.25 mm (ZB-5; Bester, Amstelveen, The Netherlands)
connected to a Agilent mass spectrometer (5975C). Cholesterol was derivatized
with N, O-Bis (trimethylsilyl) trifluoroacetamide containing 5–10% trimethyl-
chlorosilane. Isotope ratios were determined in the selected ion monitoring mode
on m/z 458 (M0) to 465 (M7).
RNA isolation and measurement of mRNA levels by quantitative
real-time PCR
Tissue samples for isolation of RNA were snap frozen in liquid nitrogen and
stored at minus 80 C˚. Samples were homogenized and total RNA using TRI-
Reagent (Sigma, St. Louis, MO, USA). RNA concentration was determined using
the Nanodrop spectrophotometer (NanoDrop 2000c, Thermo Scientific Inc.,
Walham, MA, USA). cDNA was obtained from total RNA using the RT procedure
using Moloney-Murine Leukemia Virus (M-MLV) reverse transcriptase (RT)
(Invitrogen, Life Technologies, Bleiswijk, The Netherlands) with random primers.
Gene expression was measured with a 7900HT FAST system using FAST PCR mix,
Taqman probes and MicroAmp FAST optical density 96-well plates (Applied
Biosystems Europe, Nieuwekerk ad IJssel, The Netherlands). PCR results of liver
and intestine were normalized to 36b4 mRNA levels. Primer and probe sequences
can be found at (http://www.RTprimerDB.org).
Explorative Illumina microarray analysis
For explorative microarray analysis, total hepatic RNA was prepared from
separate groups of 0.5% cholate-fed FXRa2- or FXRa4-transduced FXR knock-
out mice (n56 per group) using TRI-reagent (Sigma-Aldrich, St. Louis, MO,
USA). RNA quality and concentration was assessed with an Biorad Experion
Bioanalyzer. Starting with 200 ng of RNA, with an RNA Quality Indicator of at
least 8. RNA was amplified and labeled using the Illumina TotalPrep RNA
Amplification Kit (Applied Biosystems, Nieuwekerk ad IJssel, The Netherlands).
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The WG-6 v2 expression arrays, containing 45281 transcripts (Illumina, San
Diego, USA), were processed according to the manufactures protocol and slides
were scanned immediately. Quality control, normalization (quantile), batch
correction (Combat), prefiltering (fold change 1.1) and statistics (IBMT) were
performed in MADMAX [29]. A list of significant changed annotated genes
between FXRa2 (n56) and FXRa4 (n56), including False Discovery Rates
(FDR)-corrected p-values (10%) was generated. All microarray data reported are
described in accordance with MIAME guidelines and are available in the GEO
database (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc5GSE51805).
Identification of overrepresented functional categories among responsive genes
and their grouping into functionally related clusters was performed using the
DAVID Functional Annotation Clustering tool [30].
Western blotting for FXR protein expression
Livers were homogenized (15% w/w) in buffer containing 50 mM Tris (pH 7.4),
300 mM sucrose, 10 mM EDTA, 10 mM DTT and Complete (Roche Diagnostics,
Almere, The Netherlands). Protein was determined using BCA protein assay
(Pierce Biotechnology, Rockford, IL, USA). Total liver homogenates (25 mg
protein) for detection of FXR were electrophoresed through 7% polyacrylamide
gels and blotted on Hybond ECL membranes (Amersham, Little Chalfont, UK).
Membranes were blocked in phosphate-buffered saline (pH 7.4) containing 0.1%
Tween 20 and 4% skim milk powder. Membranes were incubated with anti-
human FXR mouse antibody (clone no. A9033A, Perseus Proteomics Inc., Tokyo,
Japan) or anti-actin (Sigma-Aldrich, St. Louis, MO, USA). After washing,
immunocomplexes were detected using horseradish peroxidase-conjugated goat
anti-mouse IgG2a (Southern Biotech, Uithoorn, The Netherlands) or Horseradish
peroxidase conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology, Delaware,
CA, USA) and SuperSignal West Dura substrate (ThermoScientific, Rockford, IL,
USA).
Statistics
Data are shown as Tukey’s Box-and-Whiskers plots or average ¡ standard
deviations. Statistical analysis was assessed using Kruskal-Wallis H test followed
by Conover post-hoc comparison or students t-test using Brightstat [31].
Results
Characterization of the mouse model
At first we established the diurnal rhythmicity and spatial expression of the four
murine FXR isoforms. Bile salt synthesis shows a strong circadian rhythm [1, 32],
but mRNA levels of hepatic FXR isoforms did not show any diurnal variation
(S1A Figure). Most prominent differences in expression between the isoforms
were observed in skeletal muscle, intestine and kidney (S1B Figure), confirming
FXR Isoforms Differentially Modulate Bile Salt Metabolism
PLOS ONE | DOI:10.1371/journal.pone.0115028 December 15, 2014 6 / 19
previous reports [5, 6], while hepatic expression of FXR isoforms was comparable.
To directly compare the physiological roles of hepatic FXRa2 and FXRa4, we
generated self-complementary adeno-associated virus particles (scAAV) expres-
sing the coding regions of murine FXRa2 or FXRa4 behind the liver-specific fatty
acid-binding protein 1 (LP1) promoter. Hepatic FXR mRNA expression (Fig. 1A)
and protein levels (Fig. 1B) were similarly induced by scAAV particle injection.
Compared to PBS-injected controls, plasma ASAT and ALAT levels were
unchanged in particle-injected mice, implying that stable scAAV transduction did
not negatively impact on liver cell integrity (Fig. 1C/D).
FXR isoforms differentially modulate lipid metabolism
The potency of hepatic FXRa2 and FXRa4 to normalize the characteristic plasma
lipid profile of FXR knock-out mice [21, 33] was evaluated first. Both isoforms
reduced the elevated total plasma cholesterol levels (table 1) seen in PBS-injected
FXR KO, FXRa2 being more effective than FXRa4 in this respect, but neither
FXRa2 nor FXRa4 completely normalized cholesterol levels to those seen in wild-
type mice. FPLC-profiling revealed reduced cholesterol levels in the VLDL-, LDL-
and particularly HDL-sized fractions of FXRa2- and FXRa4-expressing mice
compared to PBS-injected controls and wild-type mice (Fig. 1E), with FXRa2
showing the most pronounced reduction of HDL-cholesterol. Both FXRa2 and
FXRa4 caused a lowering of plasma triglyceride (TG) levels, yet, wild-type levels
were not reached in either case.
FXR isoforms differentially modulate bile salt composition
Next, we tested whether the physiochemical properties of the bile salt pool were
differentially affected by FXRa2 and FXRa4. The total amount of biliary and fecal
bile salt excretion was, surprisingly, not different between groups (Fig. 2A and C).
Yet, the bile salt profile in FXRa2-expressing mice showed a shift towards CDCA-
derived muricholates relative to CA-derived bile salts that were more prominent
in FXRa4-expressing mice (Fig. 2B and D). Specifically, biliary CA and fecal DCA
were reduced in the first, while the relative and absolute abundances of a-MCA,
CDCA and HDCA were increased (S2 Table). These data imply a shift in bile salt
synthesis towards the production of relatively hydrophilic muricholates in
FXRa2-expressing mice. Based on similar biliary and fecal bile salt excretion rates,
the latter reflecting hepatic bile salt synthesis under steady sate, it can be assumed
that the sizes of circulating bile salt pools remained unaffected upon expression of
either FXRa2 or FXRa4.
Non-biliary cholesterol excretion is enhanced in FXRa2-
transduced mice
Since muricholates are more hydrophilic than CA is, we tested whether the
differences in the hydrophobicity of the bile salt pool between FXRa2- and
FXRa4-expressing mice affect intestinal cholesterol absorption. Fecal neutral
FXR Isoforms Differentially Modulate Bile Salt Metabolism
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Fig. 1. Characterization of the PBS-injected and the liver-specific scAAV-FXRa2 or scAAV-FXRa4
transduced FXR knock-out mice. Hepatic FXR gene expression (A) and protein (B) levels in total PBS-
injected FXR knock-out mice versus stably transduced scAAV-FXRa2 or scAAV-FXRa4 FXR knock-out mice.
FXR Isoforms Differentially Modulate Bile Salt Metabolism
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sterol output was increased in FXRa2 mice compared to PBS controls and FXRa4
mice (Fig. 3). This increase was not due to diminished fractional cholesterol
absorption or increased biliary cholesterol secretion, since these were similar
between groups. Hence, the differences in fecal sterols must come directly from
the intestine, i.e., reflect the transintestinal cholesterol excretion pathway (TICE)
[34, 35]. Hepatic FXRa2 expression increased this pathway by 100% on average.
Thus, FXRa2-expressing mice showed induction in fecal neutral sterol output and
TICE without altering intestinal cholesterol absorption efficiency.
FXR isoforms differently regulate primary bile salt biosynthesis
genes
To gain insight in the modes of action by which hepatic FXRa2 and FXRa4 act on
metabolic processes, an explorative microarray was performed on the livers of
0.5% cholate-fed FXR KO mice transduced with scAAV-FXRa2 or scAAV-FXRa4.
Cholate-feeding was employed to obtain supraphysiological activation of the FXR
Dotted line in (A) represents WT FXR expression levels. Plasma ASAT (C) and ALAT (D) levels were not
altered in the AAV-treated mice compared to PBS-injected controls. (E) Cholesterol distribution in FPLC-
separated lipoprotein fractions. Values are presented in box-and-whisker plots or averages (n54–6 animals
per group). *p,0.05 vs. PBS.
doi:10.1371/journal.pone.0115028.g001
Table 1. Animal characteristics under chow-fed conditions.
FXR+/+ FXR2/2
Morphometric parameters WT PBS FXRa2 FXR4
Body weight (g) 28.0 (26.0–28.9) 27.2 (25.0–30.5) 27.1 (24.0–28.7) 26.5 (25.4–27.6)
Liver weight (% BW) 4.9 (4.5–5.5) 5.5 (4.9–6.0) 5.1 (4.3–5.5) 5.0 (4.8–5.3)
Plasma
triglycerides (mmol/l) 0.6 (0.5–1.0) 1.4 (1.0–2.6)* 1.1 (0.9–1.2)*# 0.8 (0.7–1.6)*#
cholesterol (mmol/l) 2.6 (1.9–3.1) 7.6 (7.2–7.9)* 3.7 (3.4–3.9)*# 5.8 (5.4–6.5)*#$
Liver
triglycerides (mmol/g) 10.3 (6.6–12.6) 13.6 (7.6–15.9) 7.4 (6.5–9.0)*# 8.7 (7.6–12.2)
cholesterol (mmol/g) 7.1 (6.5–8.1) 5.1 (4.7–5.4)* 6.1 (5.7–6.9)*# 6.3 (5.9–7.9)*#
Biliary output
bile flow (ml/day/100 g) 14.8 (12.9–19.5) 14.6 (10.7–16.6)* 19.2 (17.2–24.0)*# 14.6 (12.4–17.8)*#$
bile salts (mmol/day/100 g) 435.1 (262.4–518.3) 482.6 (291.8–778.4) 309.3 (258.9–
612.9)
405.7 (338.1–475.4)
cholesterol (mmol/day/100 g) 8.5 (6.4–13.2) 8.1 (5.7–8.8) 10.8 (8.4–11.7) 9.1 (7.0–11.8)
phospholipids (mmol/day/100 g) 76.6 (69.3–91.6) 79.9 (72.9–91.1) 100.6 (82.6–
122.6)*#
98.3 (84.3–148.3)*#
Animal characteristics of chow-fed FXR knock-out mice injected with PBS or stably transduced with hepatic-specific scAAV-FXR2 or scAAV-FXR4 were
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isoforms. A total of 720 probes representing 556 coding genes were identified to
represent differentially expressed genes in liver (microarray data can be obtained
from: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc5GSE51805; listed top-
Fig. 2. Physiochemical properties of the bile salt pool. Bile was canulated for 20 minutes and feces was
collected 72 hr prior to termination of chow-fed PBS-injected and the liver-specific scAAV-FXRa2 or scAAV-
FXRa4 transduced FXR knock-out mice. Total biliary (A) and fecal (C) bile salt composition are similar
between 3 groups. The biliary (B) and fecal (D) bile salt origins show differences between the 3 groups. (a-
MCA; a-muricholate, b-MCA; b-muricholate, v-MCA; v-muricholate, CDCA; chenodeoxycholate, HDCA;
hyodeoxycholate, DCA; deoxycholate, CA; cholate. We consider cholate and deoxycholate as CA-derived
bile salts and the others as CDCA-derived bile salts. Values are presented as average¡ standard deviations
(n56 animals per group). *p,0.05 vs. PBS; #P,0.05 between FXR isoforms.
doi:10.1371/journal.pone.0115028.g002
Fig. 3. Cholesterol balance. PBS-injected and the liver-specific scAAV-FXRa2 or scAAV-FXRa4 transduced
FXR knock-out mice were subjected to cholesterol kinetics using isotope labeled tracers to calculate the
contribution of dietary, biliary and intestinal cholesterol to fecal sterols. Values are presented in box-and-
whisker plots (n56 animals per group). *p,0.05 vs. PBS; #P,0.05 between FXR isoforms.
doi:10.1371/journal.pone.0115028.g003
FXR Isoforms Differentially Modulate Bile Salt Metabolism
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15 genes; S3 Table). Broad scale KEGG pathway analysis [30] revealed, as
expected, that the primary bile salt biosynthetic pathway pops up within the top 5
of most relevant pathways. Compared to expression levels seen in the livers of
FXRa4-transduced mice, FXRa2-transduced mice showed lower expression levels
of Cyp7a1 (19% reduction) and Cyp8b1 (17% reduction), indicating that FXRa2
transrepressed both Cyp7a1 and Cyp8b1 more strongly than FXRa4. Since Cyp8b1
activity is the major determinant of CA biosynthesis in the neutral branch of bile
salt synthesis, the data support the notion that hepatic FXRa2 particularly inhibits
the CA production. On the other hand, FXRa4-transduced mice showed lower
expression of Cyp7b1 (60% reduction). Since Cyp7b1 is involved in CDCA
biosynthesis via the so called acidic or alternative branch of bile salt synthesis,
these data indeed indicate that hepatic FXRa4 particularly inhibits CDCA/MCA
production, as expected on the basis of analysis of biliary and fecal bile salt
composition (S2 Table). Also Cyp17a1, a C21 steroidogenic enzyme, was
differentially regulated by the FXR isoforms (62% reduction in FXRa2 versus
FXRa4). Some of the differentially expressed genes as well as FXR itself and its
targets Shp and Abcb11/Bsep were confirmed using quantitative PCR together with
some intestinal FXR targets, in which the differences were even more pronounced
(table 2). Consistent with the shift towards CDCA-derived muricholates relative
to CA-derived bile salts in FXRa2-expressing mice, hepatic Cyp8b1 mRNA
expression was reduced compared to FXRa4-expressing mice (reduction of 33%)
and PBS-injected FXR KO (reduction of 60%). CYP7B1, the enzyme of the
alternative bile salt biosynthetic pathway, was only down-regulated in the liver of
FXRa4-expressing mice on 0.5% cholic acid-feeding. The expression of Abcb11/
Bsep also showed differential regulation by the two FXR isoforms on mRNA level.
FXRa2-expressing mice showed higher Abcb11/Bsep mRNA expression compared
to FXRa4 in both conditions. Bile flow in these animals was increased compared
to FXRa4-expressing and control mice (table 1), yet, secretion of endogenous bile
salts was unaffected implicating stimulation of bile salt-independent bile flow.
Surprisingly, the intestinal FXR target genes Fgf15 and Fabp6/Ibabp were affected
in the FXRa2- and FXR4a-transduced mice on both diets (table 2), indicating a
cross-talk between liver and intestine.
FXR isoforms differentially induce SHP in vitro
In attempt to explain the differential effects of FXRa2 and FXRa4 on Cyp8b1
expression, we have screened the promoter region of the Cyp8b1 gene for FXREs
using Mathinspector [36]. This screening revealed an IR1 FXRE in the promoter
region of murine Cyp8b1 starting at 99 base pairs from the transcription start site.
Also in the human CYP8B1 promoter region an IR1 FXRE was found, at .2500
base pairs from the transcription start site. Unlike expected, we were unable to
show direct FXR-mediated regulation of Cyp8b1 expression in promoter studies,
since FXRa2 could not transrepress the HNF-4a-activated Cyp8b1 reporter
(Fig. 4A). However, we did find that FXR isoforms differentially induce Shp
(Fig. 4B). Shp is a well-established FXR target gene whose product represses
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nuclear hormone receptor-mediated transactivation. Hence, this finding might
indicate FXR-Shp-mediated Cyp8b1 transrepression, possibly explaining the
changes in bile salt composition observed in the in vivo situation. FXR isoforms
showed differences in their transcriptional activity (FXRa2.a4.a1.a3)
Table 2. Hepatic and intestinal expression profile of genes involved in bile salt metabolism.
chow-fed 0.5% cholic acid-fed
Liver PBS FXRa2 FXRa4 PBS FXRa2 FXRa4
Nr1h4/Fxr** 1.0¡0.2 36.1¡7.1* 50.0¡14.9* 1.0¡0.5 31.9¡7.7* 29.8¡10.8*
Nr0b2/Shp 1.0¡0.3 1.8¡0.8 1.4¡1.0 1.0¡0.7 5.0¡0.8* 4.1¡1.0*
Abcb11/Bsep 1.0¡0.2 2.9¡0.2*# 2.1¡0.5* 1.0¡0.3 6.7¡0.9*# 3.8¡0.8*
Cyp7a1 1.0¡0.4 0.7¡0.3 0.6¡0.3 1.0¡0.7 0.02¡0.02 0.2¡0.1
Cyp7b1 1.0¡0.4 0.9¡0.2 1.1¡0.2 1.0¡0.4 0.9¡0.2 0.3¡0.0*#
Cyp8b1 1.0¡0.2 0.4¡0.1*# 0.6¡0.3* 1.0¡0.4 0.01¡0.01*# 0.03¡0.01*
Intestine PBS FXRa2 FXRa4 PBS FXRa2 FXRa4
Nr1h4/Fxr** 1.0¡0.2 0.7¡0.1 0.8¡0.1 1.0¡1.0 23.5¡7.7 20.9¡17.5
Fgf15 1.0¡0.7 0.4¡0.3* 0.4¡0.3* 1.0¡0.9 2.9¡1.1* 1.5¡1.0
Fabp6/Ibabp 1.0¡0.3 3.0¡0.9* 2.3¡0.9* 1.0¡0.9 2.4¡1.0* 1.2¡0.5*
Hepatic and intestinal gene expression determined by quantitative real-time PCR of genes involved in synthesis, transport and signaling of bile salts in
chow- and 0.5% cholic acid-fed PBS-injected and stably transduced scAAV-FXRa2 or scAAV-FXRa4 FXR knock-out mice. Gene expression levels were
normalized to 36b4 and corrected to expression levels of PBS-injected FXR knock-outs. Values are presented as average¡ standard deviations (n55–6
animals per group). *p,0.05 vs. PBS; #p,0.05 between FXR isoforms. ** note that our QPCR primers pairs always picked up FXR signal, even in FXR
knock-outs. Expression levels were normalized to expression levels found in PBS-injected FXR knock-out mice.
doi:10.1371/journal.pone.0115028.t002
Fig. 4. FXR-mediated transreppression of Cyp8b1 and transcriptional activity of the FXR isoforms
in vitro. Luciferase assays where performed in CV1 cells using an luciferase reporter containing tandem
copies of the FXRE from the Cyp8b1 (A) and SHP (B) genes. Activity is shown in fold induction, with the
transfection efficiencies being normalized using a dual Renilla-Firefly luciferase assay. Activity is compared to
empty vector control. Using the SHP receptor, cells were treated 24 hr post transfection either with 50 mM
CDCA or vehicle. Data are presented as average ¡ standard deviations (n$2). Significance Cyp8B1
reporter: *p,0.05 vs. control; #p,0.05 vs. HNF4a 10 ng; $p,0.05 vs. HNF4a 100 ng; &p,0.05 vs HNF4a
and SHP; ‘p,0.05 vs. HNF4a and FXRa2. Significance SHP reporter: *p,0.05 vs. control; #p,0.05 vs.
FXRa1; $p,0.05 vs. FXRa2; &p,0.05 vs, FXRa3.
doi:10.1371/journal.pone.0115028.g004
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independent of ligand activation, which was already shown in previous studies for
Abcb11/Bsep but not for Shp [5, 6]. Compared to other isoforms FXRa2 showed
an up to 50% increase in transcriptional activity upon activation using CDCA as
ligand. However, the differences in hepatic Shp expression in vivo between chow-
fed FXRa2- and FXRa4-expressing mice failed to reach statistical significance and
therefore the physiological relevance, if any, of isoform-specific Shp regulation
awaits further studies.
Discussion
The most important finding of this study is it the demonstration, for the first
time, of physiologically relevant differences in in vivo activity between the two
transcriptionally most active FXR isoforms, i.e., FXRa2 and FXRa4. Our data
demonstrate that FXRa2 and FXRa4 differentially affect transcriptional control of
bile salt and lipoprotein metabolism in mice.
One of the phenotypic hallmarks of FXR knock-out mice concerns the plasma
lipid profile with high levels of HDL-cholesterol and concomitantly elevated
VLDL-cholesterol and triglyceride levels [11]. In our model, a first biological read-
out was the (partial) normalization of this profile. Both FXR isoforms reduced
HDL- and VLDL-cholesterol levels. However, total plasma cholesterol levels in
FXRa2-expressing mice were markedly reduced compared to FXR KO values,
while FXRa4 was less effective. In both situations, cholesterol levels found in wild-
type mice were not reached, yet, the results underscore the role of hepatic FXR in
control of plasma HDL levels. The existence of relationships between bile salt and
lipid metabolism has been recognized for many years. The production of
triglyceride-rich VLDL-particles, as well as their clearance from the circulation
have been proposed to be influenced by FXR activity through modulation of
hepatic apoc2/apoc3 expression [37, 38] as well as VLDLR expression in cells [39].
On the other hand, bile salt-activated FXR lowers HDL-cholesterol, which has
been attributed to suppression of Apoa1 expression [40] and, very recently, to
suppression of CETP expression which is, however, not expressed in wild-type
mice [41]. The explorative microarray data of 0.5% cholic acid-fed FXRa2- and
FXRa4-expressing mice revealed small but significant differences in hepatic Apoc2
(20% upregulated in FXRa2) and Vldlr (30% upregulated in FXRa4) expression
(S3 Table). Although relatively small, these differences indicate differential
regulation of VLDL production as well as clearance from the circulation. Recently,
the triglyceride-lowering capacity of FXR was linked to synthesis of 12a-
hydroxylated bile salts via Foxo1, a key regulator of glucose metabolism [42].
Murine Foxo1 ablation caused elevated liver and plasma triglyceride levels, two
signature lipid abnormalities of diabetes and the metabolic syndrome. These
changes were associated with a relative deficiency of 12a-hydroxylated bile salts
and in expression of Cyp8b1. In diabetes, the impaired insulin response led to
dysfunctional Foxo1, which drives bile salt synthesis towards 12a-hydroxylated
bile salts, leading to an abnormally hydrophilic bile salt pool affecting cholesterol
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and triglyceride metabolism. These data coincide with those observed in our
model: FXRa2-expressing mice showed a stronger transrepression of Cyp8b1
compared to FXRa4, thereby generating less 12a-hydroxylated bile salts and their
plasma triglyceride levels tended to be higher than in FXRa4-expressing mice
(table 1). Furthermore, FPLC data revealed slightly lower HDL-cholesterol in
FXRa2-expressing mice compared to those expressing FXRa4. Thus, FXRa2 was
found to target primarily the neutral branch of the bile salt biosynthesis pathway
by transrepressing Cyp7a1 and Cyp8b1, thereby inhibiting CA production. FXRa4,
on the other hand, was found to particularly suppress the acidic branch of the bile
salt biosynthesis pathway Cyp7b1, targeting primarily CDCA and MCA synthesis.
The changes in expression levels were consistent with compositional changes in
the bile salt species in bile as well as in feces. The changes in bile salt composition
alter the physiochemical properties of the bile salt pool. FXRa2 mice generate a
more hydrophilic bile salt pool compared to FXRa4. In the cholate-fed situation,
i.e., a state of FXR activation, also Cyp17a1 was found to be differentially
expressed by FXRa2 and FXRa4. FXRa2-expressing mice transrepressed Cyp17a1
62%more compared to FXRa4. Recently, increased production of 17-hydroxy
steroid metabolites, the product of Cyp17a1, have been associated with juvenile
onset cholestasis [43]. We did not observe large differences in bile flow or the
grade of liver damage between the FXR isoforms that might indicate onset of
cholestasis.
In the bile salt pool of Cyp7a1- as well as Cyp8b1-knock-out mice, in which CA
was largely replaced by MCA, fractional cholesterol absorption from the intestine
was decreased [44] while the intestinal cholesterol synthesis was induced [45] as a
rescue mechanism. Since we observed similar alterations in bile salt pool
composition in the FXRa2 mice, we analyzed cholesterol kinetics [24] to
determine whole body cholesterol balance. Our data show increased fecal neutral
sterol output in FXRa2-expressing mice, without concomitant reduction of
fractional cholesterol absorption. Since there was no difference in biliary
cholesterol secretion between FXRa2 and a4 -expressing mice, increased TICE
accounted for the difference in neutral sterol excretion. The question arises how
FXRa2 induces this effect. Our data show a differential effect of the FXR isoforms
on plasma lipoprotein and bile salt pool distribution. Regulatory effects of plasma
lipoproteins on the rate of TICE have not been described and the (lipoprotein)
donor of TICE has still not been identified [46, 47]. The influence on the
hydrophobicity of the bile salt pool may be more important. In vitro studies have
shown that the presence of bile salts in the intestinal lumen, particular when
combined with phospholipids, strongly stimulate this pathway but a clear
influence of bile salt hydrophobicity was not demonstrated. A clear association
between bile salt hydrophobicity and cholesterol absorption has been observed
[48]. However, apparently in the present study the changes in the hydrophobicity
of the bile salt pool were too subtle to affect cholesterol absorption. Hence it is not
inhibition of cholesterol absorption that induces the increase in TICE but another
as yet unidentified factor must be involved. We do speculate, however, that the
change in the hydrophobicity of the bile salt pool drives the effect on TICE.
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FXR regulates bile salt hydrophobicity via modulation of Cyp7a1 and Cyp8b1
expression through a SHP/LRH1- and HNF-4a-dependent pathway. To explain
our results we speculated that FXR would directly transrepress Cyp8b1 without
interference of SHP. Promoter region analysis using Mathinspector [36] revealed
a FXRE (agggcaggaacct) in the promoter region of both murine and human
CYP8B1. Reporter studies, however, did not confirm direct FXR-mediated
regulation of Cyp8b1 expression using our murine FXR isoforms. Although
hepatic gene expression of SHP did not significantly differ between the FXR
isoform-transduced mice in vivo, our in vitro studies did show differential
induction of SHP by both FXR isoforms. SHP is an orphan nuclear receptor that
is regulated by many other nuclear receptors and transcription factors involved in
metabolism and cancer [49] and also has been shown to be involved in control of
Cyp8b1 expression [50]. SHP can repress transcription factor-mediated transac-
tivation by inhibiting DNA binding, competing for binding of coactivators or
recruitment of corepressors. Hepatic SHP mRNA expression shows circadian
rhythmicity, regulated by the clock gene Nr1d1(Rev-erba) [51]. Because of the
interaction with many other transcription factors and the circadian rhythmicity,
the in vivo regulation of SHP is complex. Our laboratory very recently
demonstrated that human FXR regulates SHP expression through direct binding
to an LRH-1 binding site, independent of the known IR-1 and LRH-1 sites [52],
which underscores the fact that the exact mechanisms by which SHP is regulated
in vivo remains enigmatic. The differences in transcriptional activation of SHP,
i.e., FXRa2 being more effective than FXRa4, may contribute to the differences
observed in hepatic Cyp8b1 expression, resulting in the concomitant differences in
the bile salt pools between FXRa2- and FXRa4-expressing mice. Yet, more studies
are required to substantiate this suggestion.
The intriguing question remains why FXR isoforms exist and what their specific
physiological roles in different tissues actually are. FXRa2 and FXRa4 differ
within their N-terminal parts, i.e., a 37 amino acid extension of FXRa4 compared
to FXRa2. This difference can cause conformational changes in the FXR protein
and, thereby, influence the transcriptional activity and/or transactivation/
repression capacity on target genes. A dozen transcriptional cofactors have been
described to influence FXR transactivation [53], but actions specific for the
specific FXR isoforms have not been described. The relative abundance of hepatic
FXRa3,4 was increased in children suffering from progressive familial cholestasis
type I [54]. Also in cholangiocarcinomas [55] and colorectal adenocarcinoma [56]
the relative abundance of hepatic and intestinal FXRa3,4 was increased.
Apparently, disease states can be associated with a switch in FXR isoform
expression in the liver and intestine which may influence outcome of disease
progression. Recently, Vaquero et al. [57] reported that activation of human FXR
depends on the pattern of FXR isoform expression and bile salt composition. They
showed that cell-specific pattern of FXR isoforms determine the overall tissue
sensitivity to FXR agonists and may be involved in the differential response of
FXR target genes to FXR activation. The present study shows that the FXR
isoforms influence physiology differentially and although murine and human bile
FXR Isoforms Differentially Modulate Bile Salt Metabolism
PLOS ONE | DOI:10.1371/journal.pone.0115028 December 15, 2014 15 / 19
salt and lipoprotein metabolism differ from each other the differential influence of
the isoforms on the bile salt synthesis pathways will probably be similar.
In conclusion, we show for the first time physiological evidence for differential
roles of FXRa2 and FXRa4 in control of bile salt and lipoprotein metabolism in
mice. This might, in light of the increasing evidence for therapeutic potential of
FXR agonists, be of importance for design of treatment strategies for metabolic
diseases.
Supporting Information
S1 Figure. Spatial and tissue-specific expression profiles of FXR isoforms in
mice. Relative expression was measured in livers from mice sacrificed at different
time point during the day (A), in different tissues at 13:00 h (B). Gene expression
levels were normalized to 36B4. Data are presented as average ¡ standard
deviation (n56–7 animals per group). *p,0.05 between FXRa1/2 and FXRa3/4.
Wat; white adipose tissue, bat; brown adipose tissue, liv; liver, skm; skeletal
muscle, kid; kidney, int; small intestine.
doi:10.1371/journal.pone.0115028.s001 (DOCX)
S1 Table. Primer list. Overview of the conventional primers used for cloning the
different murine nuclear receptors. The FXRa1, FXRa3, RXRa, SHP and HNF4a
primers were used to clone the FXRa1, FXRa3, RXRa, SHP and HNF4a genes.
The FXRa2/4 primers were designed as nested primers to delete the four amino
insertion in the hinge region of FXRa1 and FXRa3 to generate FXRa2 and FXRa4,
respectively.
doi:10.1371/journal.pone.0115028.s002 (DOCX)
S2 Table. Biliary and fecal bile salt profiles. The specific bile salts in bile and
feces were determined by gas chromatography and are presented as mmol/day/
100 g body weight as average ¡ standard deviation (n55–6). *p,0.05 vs. PBS-
injected FXR KO; #p,0.05 between FXR isoforms.
doi:10.1371/journal.pone.0115028.s003 (DOCX)
S3 Table. Differentially expressed genes of explorative Illumina microarray of
livers of 0.5% cholic acid-fed stably transduced scAAV- FXRa2- and scAAV-
FXRa4-FXR knock-out mice. Livers of 0.5% cholic acid-fed stably transduced
scAAV- FXRa2- and scAAV-FXRa4-FXR knock-out mice were used for
explorative microarray analysis. Listed top-15 genes and interesting targets, which
showed statistically significant differences with a False Discovery Rate (FDR)
,10%. ‘‘Fold change’’ represents the fold difference in expression between livers
of stably transduced scAAV-FXRa2-and scAAV-FXRa4 FXR knock-out mice
(both n56). The genes represented in bold are involved in bile salts and lipid
metabolism.
doi:10.1371/journal.pone.0115028.s004 (DOCX)
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